FiberNEW2026-09

Context-dependent functionality of 2'-fucosyllactose with Bifidobacterium breve M-16 V and short-chain galacto-/long-chain fructo-oligosaccharides in infant gut fermentation.

Guo Wenbo, Zhou Binghui, An Youlan, Qiu Huiying et al. — Food research international (Ottawa, Ont.)

Summary

This study explored how a beneficial sugar found in human milk, 2'-fucosyllactose (2'-FL), works in an infant's gut. It found that 2'-FL is more effective at promoting healthy gut bacteria and reducing inflammation when combined with other prebiotics (like those in infant formula) and a specific beneficial bacterium, Bifidobacterium breve. This suggests that the benefits of certain fibers for gut health can be enhanced when they are part of a supportive mix.

AI-generated summary — read the original

Key points

A human milk sugar called 2'-fucosyllactose (2'-FL) supports infant gut health.
2'-FL works better when combined with other prebiotics and a specific beneficial bacterium, Bifidobacterium breve.
This combination significantly increased beneficial gut bacteria and reduced markers of inflammation.
The study highlights that the effectiveness of prebiotics can depend on their microbial environment.

What the study looked at

What question the study asked: This study investigated whether a beneficial sugar found in human milk, called 2'-fucosyllactose (2'-FL), could be more effective at promoting a healthy infant gut when combined with other common prebiotics and a specific beneficial bacterium. Researchers wanted to know if 2'-FL's ability to support good bacteria and reduce inflammation would improve in a more complex, supportive environment. How it was studied: Scientists used an artificial gut system in the lab, which mimicked the conditions of an infant's gut. They introduced gut microbes from infant stool samples into this system. They then tested five different combinations of 2'-FL, a mix of short-chain galacto-oligosaccharides and long-chain fructo-oligosaccharides (scGOS/lcFOS, often found in infant formula), and the beneficial bacterium Bifidobacterium breve. They observed how these combinations affected bacterial growth, the production of beneficial compounds, and inflammatory responses. What it found: The study found that 2'-FL alone had limited effects. However, when 2'-FL was combined with both scGOS/lcFOS and Bifidobacterium breve, it significantly boosted the growth of beneficial Bifidobacterium while reducing potentially harmful bacteria. This combination also led to increased production of beneficial short-chain fatty acids and compounds that help reduce inflammation. These results suggest that 2'-FL's positive effects are enhanced when it works together with other prebiotics and specific beneficial bacteria.

Dietary takeaway

This study highlights that the benefits of dietary fibers, like the oligosaccharides studied here, might be maximized when consumed as part of a diverse diet that supports a variety of beneficial gut bacteria. For adults, this could mean aiming for a wide range of plant-based foods rich in different types of fiber, rather than relying on a single source. Remember, this is an in-vitro study, and while promising, more research in humans is needed to confirm these findings.

Abstract

Human milk oligosaccharides, particularly 2'-fucosyllactose (2'-FL), are important functional components involved in infant gut microbiota development and immune-related functions. However, the efficacy of 2'-FL may be limited when applied alone, especially in microbiotas with insufficient 2'-FL-utilizing bacteria. This study investigated how the functional performance of 2'-FL changed when incorporated into a short-chain galacto-oligosaccharides/long-chain fructo-oligosaccharides (scGOS/lcFOS)-supported system containing Bifidobacterium breve M-16 V. A continuous in vitro fermentation system was inoculated with fecal microbiota from four donors selected from 22 infant volunteers. Five treatments were compared: 2'-FL, GF (scGOS/lcFOS), GFB (GF + B. breve), GFF (GF + 2'-FL), and GFFB (GF + 2'-FL + B. breve). 2'-FL alone showed limited bifidogenic activity and weak support for microbial growth, whereas GFFB increased Bifidobacterium to 205.62% of the day-10 stabilization baseline (P < 0.01) and reduced Pseudomonadota to 14% of baseline (P < 0.001). GFFB also increased acetate to 140% of the 2'-FL group (P < 0.01), increased propionate to 110% of baseline (P < 0.05), and enriched tryptophan-derived indoles. Immunomodulatory activity was evaluated using cell-free fermentation supernatants rather than direct ingredient exposure. GFFB-derived supernatants showed the strongest attenuation of LPS-induced inflammatory responses in RAW 264.7 macrophages, reducing IL-1β, IL-6, nitric oxide, and TNF-α to 26.70%, 57.50%, 29.84%, and 35.91% of the LPS control, respectively (all P < 0.001). These findings indicate that the functional expression of 2'-FL was broadened in an scGOS/lcFOS-supported microbial context containing B. breve M-16 V.

View on PubMed →DOI: 10.1016/j.foodres.2026.120387